Exhibition Report | Haibu PharmaceuticΩ©♠al Debuts at the 2024 6th CMC-China✘​ Expo

Classification:

Company News

Release time:

2024-08-19

On August 15-16, 2024,£≠α≠ the 6th CMC-China Expo will<∑ε₽ be grandly held at the Suzhou Int ↕§↕ernational Expo Center!Haibu Pharmaceutical (Bπ₽♠&ooth No.: C-H10-1) is on≤φ&e of the exhibiting companies at t☆÷his event. This expo has gathered♦$←& many leading domestic pha×‍rmaceutical companies, res©•↑earch institutions, and industrγ↕y experts. The exhibition site i$±±s bustling with visitors, and♠★♣ all major thematic ↕≠ §forums are fully seated witφ'≥φh a lively atmosphere.
 
Exciting moments at the Hai→≠bu booth
This CMC exhibition has pro​♥♥₩vided Haibu Pharmaceutical₹×∞φ with a more direct an±§d in-depth communication pla↑>φtform with many new ✔ and old clients. The Haibu boothε♥ was busy with people, and the atmosphπ♥ere of communication was w<α>arm. We sincerely thank every friend ¶₽who visited our booth; your trust a§♦♠÷nd support are our inexhaus♠α♦tible motivation on the road¥← ahead.
In the future, Haibu Pharmaceutical ∑ will remember the business philosoph§δ✔y of 'integrity, professionalism, c₽×₹ooperation, and win-win' and c✘± ontinuously enhance its R&a αα£mp;D innovation capabilities.←σ We will actively build a high ₽-barrier technology platfo∑>rm with cost advantages and tec¥λ₩hnical advantages to p♣♦rovide better quality•↑∑ products and services to our custome​↔rs.

Beijing Haibu Pharmaceutical Tec ₽±hnology Co., Ltd. (referred to€γ‍♦ as 'Haibu Pharmaceuti♣$cal') was established in ✘∑€"2005 and is a high-tech enterp£₹×±rise focused on 'chemic ®¶↑al drug R&D' as its core capa≠₹§☆bility. It has a researcλ₽↔h center in Beijing,± $​ an API and formulation pilot validatio↕¥n center, and a GMP industrialπφ production base.It mainly engages in API and formulatioγ£n CRO services, MAH formulationσ≈ R&D and licensing, API-rσ★elated registration and commercial$Ω​™ supply, innovative a÷& nd improved drug R&D applications ★≠‌, etc., having been aw↔∞®♠arded the title of 'To±Ω≈ p 20 Chinese Pharmaceutical  ≈¥ R&D Companies' for s≠ ♠everal consecutive years. It has b∑♥✘een recognized as a 'Beijing Science ¥‍¥ and Technology Research De§£velopment Institution', 'Nationa•™l High-tech Enterprise', 'Beijing Yi∑•zhuang Enterprise In<£novation Center'.

Haibu Pharmaceutical has rich experienc®σ✘☆e in the R&D transfer production, ∞♣registration applicationε≤ φ of various dosage forms<¥♦→ such as chemical APIs,¥₽ oral solids, liquid formulations‍≤, sterile injections, external preparat≤€₹←ions, etc. The R&D p₽  roducts cover multiple th©♠erapeutic areas includingδ¥ anti-tumor, anti-depressi€♦<¥on, anti-epilepsy, anti-an☆÷≠xiety, cardiovascular &aπ>&£mp; cerebrovascular diseas™→←es, digestive system disorders, respλ™iratory system issues.

Previous Page

Heading to Europe | H"€aibu Pharmaceutical Shines at CPHI Mil♣↕→✔an 2024

Previous Page

Heading to Europe | Haibu Pharmac§€♠eutical Shines at CPHI Milan 2024